Results 151 to 160 of about 1,343 (178)

Cell-Free DNA Fragmentomics: The Novel Promising Biomarker

open access: yesInternational Journal of Molecular Sciences, 2023
Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and active release mechanisms, which carry the genetic and epigenetic information of its origin tissues. However, cfDNA is the mixture of various cell fragments, and the efficient enrichment of cfDNA fragments with diagnostic value remains a great challenge for ...
Qinyu Ge, Min Pan, Yunfei Bai
exaly   +4 more sources

Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer [PDF]

open access: yesInternational Journal of Molecular Sciences, 2022
Identifying novel circulating biomarkers predictive of response and informative about the mechanisms of resistance, is the new challenge for breast cancer (BC) management.
Ugo De Giorgi   +2 more
exaly   +2 more sources

Fragmentomics of Proteins and Natural Oligopeptides

Biophysics, 2008
The term fragmentomics is grounded and defined. Theoretical structure-function analysis of all possible fragments of a protein molecule was performed under the concept of fragmentomics to determine the regions that could be potential sources of regulatory oligopeptides.
A A Zamyatnin
exaly   +4 more sources

Cell-Free DNA Fragmentomics in Cancer

open access: yesCancer Cell
The analysis of cell-free DNA (cfDNA) fragmentation patterns, known as "fragmentomics," has opened new opportunities in noninvasive cancer diagnostics. Due to its close relationships with genomic organization and cell death, cfDNA fragmentomics lies at the intersection of many aspects of cancer biology, including epigenetic dysregulation ...
Peiyong Jiang   +2 more
exaly   +3 more sources

Fragmentomics Features of Ovarian Cancer

open access: yesInternational Journal of Cancer
AbstractOvarian cancer (OC) is a major cause of cancer mortality in women worldwide. Due to the occult onset of OC, its nonspecific clinical symptoms in the early phase, and a lack of effective early diagnostic tools, most OC patients are diagnosed at an advanced stage.
Lei Li, Jing Wang, Huanwen Wu
exaly   +3 more sources

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Science, 2021
Enhancing liquid biopsies Liquid biopsies, analyses of cell-free DNA that circulates in the blood, can be used in prenatal testing, oncology, and to monitor organ transplant recipients. Lo et al.
Y. M. Dennis Lo   +3 more
openaire   +2 more sources

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology, 2023
The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment.
K T, Helzer   +33 more
openaire   +2 more sources

Longitudinal Profiling of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Through Droplet Digital PCR-Based Circulating Tumor DNA Fragmentomics [PDF]

open access: yesTranslational Oncology
Background: In the context of hormone receptor positive, HER2 negative Metastatic breast cancer (MBC), CDK 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the standard first-line treatment, improving Progression-Free Survival (PFS) and
Alessandro Marco Minisini   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy